



With an increased emphasis on research design & evidence based data driven insights, clinical biostatistics remains an integral part of our services and solutions. At Cliantha, our team of biostatisticians and statistical programmers provides you the operational and strategic statistics that are scientifically accurate, validated and reproducible.

In addition to standard BA/BE and Clinical endpoint studies, Cliantha has now increased its capability for statistical analysis of below mentioned studies:

- Toxicology Carcinogenicity studies
- In-vitro dissolution bootstrap data analysis (f2 factor)
- In-vitro dissolution profile comparisons (using Model Independent Approach Using a Similarity Factor, Model Independent Multivariate Confidence Region Procedure)
- In-vitro kinetic binding and equilibrium binding studies
- In-vitro comparative Nasogastric (NG) tube studies
- In-vitro Population Bioequivalence analysis (PBE) (as per Budesonide Suspension/Inhalation, Azelastine hydrochloride; Fluticasone propionate Spray, metered; Nasal)
- Analysis of assay stability data
- Cut-off with sensitivity-specificity analysis
- Screening Cut point, Confirmatory Cut point and Sensitivity analysis for immunogenicity assay
- DRC (ED50)-Vasoconstriction studies
- Adhesion, Irritation, Sensitization (HRIPT) studies
- SAD-MAD phase I studies
- Consumer research studies

For more information reach us: info@cliantha.com